Sign Up

Pharmaceutical interventions for weight-loss maintenance: No effect from cabergoline

NZ Research Abstract

posted by WM Admin on 15 August 2018


Patrick J. Manning
David R. Grattan
Tony R. Merriman
Thomas Manning
Sheila M. Williams
Wayne H. F. Sutherland

Year of Publication



International Journal of Obesity, 6 August [Epub before print]

Publication Type

Journal article (peer reviewed)

Publication Status



The authors tested the hypothesis that dopamine agonist treatment would prevent weight regain following acute weight loss in individuals with obesity. The 2-year double blind randomised controlled trial compared the effect of a dopamine agonist, cabergoline, with placebo on weight regain in obese individuals who had lost at least 5% of their body weight using an 800‚ÄČkcal/day commercial meal replacement programme. They conclude that "treatment with the dopamine agonist cabergoline does not prevent weight regain in obese individuals following weight loss".

Type of Study

Randomised controlled trial

How to Access

To read the full abstract and for information on how to access the full text, go to: or contact your DHB library, or organisational or local library for assistance.